BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123356
Published online Nov 15, 2026. doi: 10.4251/wjgo.123356
Table 1 Baseline clinicopathological characteristics of the study cohort (n = 254), n (%)/mean ± SD

lesser curvature lymph node ≤ 7 (n = 96)
lesser curvature lymph node > 7 (n = 158)
P value
Age (year)0.670
    < 6538 (39.58)57 (36.08)
    ≥ 6558 (60.42)101 (63.92)
Sex0.615
    Female22 (22.92)42 (26.58)
    Male74 (77.08)116 (73.42)
Differentiation0.858
    Poor33 (34.38)50 (31.65)
    Moderate59 (61.46)99 (62.66)
    Well4 (4.17)9 (5.7)
T stage0.925
    T124 (25)40 (25.32)
    T217 (17.71)25 (15.82)
    T355 (57.29)93 (58.86)
N stage0.767
    N064 (66.67)105 (66.46)
    N126 (27.08)46 (29.11)
    N26 (6.25)7 (4.43)
TNM stage1.000
    I23 (23.96)37 (23.42)
    II73 (76.04)121 (76.58)
Perineural invasion1.000
    Yes57 (59.38)95 (60.13)
    No39 (40.63)63 (39.87)
Vascular invasion0.166
    Yes47 (48.96)62 (39.24)
    No49 (51.04)96 (60.76)
Tumor size (cm)3.99 ± 2.483.60 ± 1.730.511
Total LN count17.91 ± 5.3423.44 ± 6.94< 0.001
BMI (kg/m2)0.324
    < 2359 (61.46)108 (68.35)
    ≥ 2337 (38.54)50 (31.65)
Smoke0.623
    Yes25 (26.04)47 (29.75)
    No71 (73.96)111 (70.25)
Drink0.942
    Yes20 (20.83)31 (19.62)
    No76 (79.17)127 (80.38)
CEA (ng/mL)0.680
    < 580 (83.33)136 (86.08)
    ≥ 516 (16.67)22 (13.92)
CA199 (μg/mL)1.000
    < 2784 (87.5)138 (87.34)
    ≥ 2712 (12.5)20 (12.66)
Tumor location0.788
    Upper37 (38.54)55 (34.81)
    Middle31 (33.29)57 (36.08)
    Lower28 (29.17)46 (29.11)
Postoperative chemotherapy0.422
    Yes38 (39.58)72 (45.57)
    No58 (60.42)86 (54.43)


Write to the Help Desk